12results about How to "High infection efficiency" patented technology

The application provides an AAV9 capsid protein variant and use thereof. Research finds that the AAV9 capsid protein is modified, and the modified amino acid sequence is shown in SEQ ID NO: 1, which can significantly escape neutralizing antibodies, and has significant positive significance for gene therapy.

This invention discloses a recombinant oncolytic virus based on a Luyo virus G protein mutation and its large-scale production method. The method involves using reverse genetics to replace the G protein-coding gene of a wild-type oncolytic vector with a mutated Luyo virus G protein-coding gene, while simultaneously inserting a functional cytokine-coding gene into the wild-type oncolytic vector, thereby rescuing and obtaining a self-replicating recombinant oncolytic virus. The sequence of the mutated Luyo virus G protein-coding gene is shown in SEQ ID No. 1. This invention retains ideal therapeutic properties and achieves efficient amplification in interferon signal-deficient cells, facilitating titer determination.

The invention discloses application of a soybean histone variant to improvement of genetic transformation efficiency of soybeans and other plants. By applying the soybean histone variant, the infection efficiency of agrobacterium to soybean cotyledonary node explants can be remarkably improved, so that efficient introduction of exogenous genes is promoted, the transformation efficiency is remarkably improved, finally, the higher stable transformation rate is obtained, and the application can be expanded to recalcitrant plant species with genetic transformation difficulty such as tea. In addition, the subsequent genetic transformation efficiency can also be remarkably improved by using the genetic transformation material for stable overexpression of the soybean histone variant as a receptor.

The invention relates to an anti-Theras gene derived from a cold spring, a screening method, an activity determination method and application of the anti-Theras gene, and particularly discloses an anti-Theras gene derived from the cold spring, and the nucleotide sequence of the anti-Theras gene is shown as SEQ ID NO: 1. According to the application, a novel anti-Theras gene is identified from a deep sea cold spring environment for the first time, and heterologous expression and plaque experiments prove that the novel anti-Theras gene can effectively antagonize a Theras defense system of a host. According to the anti-Theras gene provided by the invention, the types and sources of anti-defense genes are expanded, and a gene blank for non-classical defense system Theras from a cold spring environment is provided.

The invention provides an AAV9 capsid protein variant and application thereof. Researches find that the AAV9 capsid protein is modified, the modified amino acid sequence is shown as SEQ ID NO: 1, and the AAV9 capsid protein can significantly escape a neutralizing antibody and has significant positive significance for gene therapy.

This invention discloses a viral vector targeting KIF4A to inhibit angiogenesis, its preparation method, and its applications. The viral vector contains three shRNA gene fragments targeting the KIF4 protein-coding region, as shown in SEQ ID NO.1-SEQ ID NO.3. Using a lentiviral packaging system, a stable KIF4A knockdown cell line can be constructed, effectively inhibiting endothelial cell proliferation and angiogenesis, and also inhibiting the paracrine promotion of angiogenesis by glioma cells, providing a new strategy for selecting targets for anti-angiogenic tumor therapy.

The application provides an AAV9 capsid protein variant and use thereof. The inventors have found, through research, that by modifying the AAV9 capsid protein, changing the amino acid sequence of the capsid protein to a sequence as shown in SEQ ID NO: 3, the infection capacity can be significantly improved, especially the transduction efficiency in the liver, thereby providing a new prospect for gene therapy.

This invention belongs to the field of agricultural microbiology technology, specifically relating to *Pseudomonas vensuelae* (…). Pseudocitrobacter vendiensis This invention relates to Pv-LC32 and its application in enhancing the pathogenicity of *Metarhizium anisopliae* against locusts. For the first time, this invention isolates a strain of *Pseudomonas vensuelae* from the midgut of locusts, exhibiting conditional synergistic pathogenicity. This strain does not directly kill the host, but significantly enhances fungal infection efficiency through interaction with *Metarhizium anisopliae*. This discovery provides a new perspective on understanding the interaction mechanism between insect gut symbiotic bacteria and pathogenic fungi, and lays a theoretical foundation for developing biocontrol enhancement technologies.

The application provides a composition, a method and an application for improving the titer of mouse leukemia virus, and belongs to the technical field of biotechnology.The method comprises the following steps: before a host cell is infected with xenotropic mouse leukemia virus, the host cell is pretreated by using SC79; during virus infection of the pretreated host cell and during cell passage, mifepristone is added to a culture medium; and during continuous virus harvesting, LR3 IGF-1 is added to the culture medium.Through adding additives with different functional mechanisms at different stages of virus production, the application realizes dynamic optimization of the whole process of virus production.The experimental results show that the combination of SC79, mifepristone and LR3 IGF-1 can increase the titer of xenotropic mouse leukemia virus by 14.32 times, which is significantly better than the effect of single additive or two additives in combination.The application solves the problems of low titer of virus stock solution and low production efficiency in the prior art.

The present application belongs to the technical field of crop breeding, and relates to a potato breeding method for editing ALS gene. The method comprises the following steps: (1) using agrobacterium transformed with a gene editing tool to infect potato explants, wherein the infection medium used contains CaCl2 with a total concentration of 9-15 mM, and the gene editing tool targets potato ALS gene for editing mutation of ALS gene to make potato resistant to imidazolinone herbicides; (2) after co-cultivation and recovery culture, the potato explants are sequentially subjected to resistant callus induction, resistant bud induction and seedling culture on resistant callus induction medium, resistant bud induction medium and seedling medium to obtain regenerated seedlings, and the resistant callus induction medium, resistant bud induction medium and seedling medium all contain imidazolinone herbicides. By using the method of the present application, potato varieties with ALS gene mutation can be obtained with high infection efficiency and high gene editing efficiency.

The invention belongs to the technical field of microorganisms, and discloses an NTase protein, a screening method thereof and application of the NTase protein in preparation of an anti-phage signal system antagonist and / or an antibacterial preparation. The NTase protein provided by the invention specifically comprises an amino acid fragment with a sequence as shown in SEQ ID NO: 1 or a variant fragment with at least 70% sequence identity with the sequence as shown in SEQ ID NO: 1, the NTase protein has an excellent antagonistic effect on a CBASS system of prokaryotes, and the infection efficiency of viruses on prokaryotic cells can be improved by inhibiting the CBASS system; therefore, a better antibacterial effect is achieved, and the compound has a very excellent application prospect in research and development of novel antibacterial drugs.

The invention relates to the technical field of cell culture, and discloses a tracheal epithelial cell and application thereof, the cell is a guinea pig tracheal epithelial immortalized cell, and the preservation number is CGMCC No. 46763. In the invention, the cell has good susceptibility to respiratory pathogens, and has excellent transfection efficiency. The cells can be used for separating or culturing respiratory pathogens, preparing respiratory pathogen vaccines, screening and / or preparing medicines for preventing and / or treating diseases caused by the respiratory pathogens, serving as host cells for researching the respiratory pathogens, detecting the respiratory pathogens for a non-diagnostic purpose and constructing organoids. The method has high scientific research value and practical application potential.